Data from an in vitro study presented at the Fourth China Medical Biotech Forum, in Dalian, China indicate that stem cells found in menstrual blood (known as MenSCs) proliferate rapidly and have significant potential to develop into multiple cell types. Dr. Julie Allickson, Vice President of Laboratory Operations and Research and Development at Cryo-Cell, presented the data at the Forum as part of a keynote address.
The Forum invites officers from related government departments of China to report on key issues and relevant policies regarding the development of medicinal biotechnology. It also provides renowned scientists the opportunity to make presentations on their latest progress. Presentations focus on topics such as vaccine separation, purification and application; antibody and peptide drug research and clinical application; the latest developments of enzyme engineering and fermentation engineering; as well as regenerative medicine technology research and its standard, nanobiotechnology research.
The information Dr. Allickson presented is based on research conducted by Cryo-Cell International, who discovered the menstrual stem cells. The data shows that MenSCs have the capability to differentiate rapidly and plentifully into stem cells such as bone, cartilage, fat, nerve and cardiogenic cells. These findings demonstrate that menstrual stem cells are easily expandable to clinical relevance and may potentially have applications in a variety of conditions. Using Cryo-Cell’s C’elle system, MenSCs are currently being studied for potential therapeutic applications for possible future treatment of disorders such as stroke, diabetes, vascular regeneration, breast cancer, endometriosis, and female urinary incontinence, as well as wound management.
"MenSCs are sufficiently potent and could potentially be used in the future for a variety of therapies and conditions, and we look forward to gaining further insights from the current clinical trials testing the safety and efficacy of the cells in several different animal models," said Dr. Allickson.
Cryo-Cell’s C’elle service was introduced in November 2007 as the first and only service that whereby women can collect and cryopreserve stem cells from menstrual blood. The fluid contains undifferentiated adult stem cells for future utilization by the donor or possibly first-degree relatives in a manner similar to umbilical cord blood stem cells.
Cryo-Cell reports that it is actively expanding its portfolio of research collaborations with world-renowned scientists committed to study this stem cell population for a broad range of regenerative therapeutic applications and treatments.